Back
Insmed Incorporated (INSM)
BiotechnologyINSM · NASDAQ NMS - GLOBAL MARKET · USD
New to investing? How to read this page →$100.66
+0.09%Weekly undervalued picks
Price · 1 year
Loading live analysis…
Loading analysis…
Intrinsic Investor is for research and education only. Not financial advice.
Key metrics
EPS
$-6.42
ROE
-294.5%
Gross margin
81.8%
Debt/Equity
1.05x
Revenue growth
229.6%
Insmed Incorporated — company intelligence
Earnings surprises
Q2 2026$-0.06 vs $-0.80 est+92.5%
Q1 2026$-0.76 vs $-0.98 est+22.3%
Q4 2025$-1.54 vs $-1.32 est-17.0%
Q3 2025$-1.75 vs $-1.37 est-28.1%
Analyst consensus · 30 analysts
29 Buy1 Hold0 Sell
Updated Oct 6, 2026
Insider activity · 90 days
0 buys5 sellsnet -280,550 shares
Brennan David RSell 25,000 · Sep 9, 2026
SHAROKY MELVIN MDSell 5,000 · Aug 17, 2026
Adsett Rogerother 82,280 · Aug 10, 2026
Recent SEC filings
8-K — Material event reportOct 5, 2026
4 — Insider transaction reportSep 11, 2026
4 — Insider transaction reportAug 19, 2026
Latest news
What BioPharma Credit (BPCP) Said on Its H1 Earnings Call — Yahoo · 2w ago
Goldman Sachs Reinstates Buy on Insmed, Announces $188 Price Target — Benzinga · 2w ago
Can LQDA's Yutrepia Outpace Intensifying PAH Competition? — Yahoo · 2w ago
FDA Accepts Insmed's Filing Seeking Label Expansion for Arikayce — Yahoo · 2w ago
Insmed: Expensive Stock, But Discount To Recent Highs Makes Bull Case — SeekingAlpha · 2w ago
AI Valuation Narrative
Generates a short bull / bear / catalyst summary from the analytics we already computed. No target prices. Research tool, not investment advice.
Explore more
Peers & similar stocks
Quick links to related tickers for research.
Weekly undervalued picks
Get 3 new value ideas and the fair-value math behind them every week. One email, unsubscribe anytime.
Free. No spam. We only email once per week.
Data is provided "as-is" and may be delayed or incomplete. Intrinsic Investor is for education only and is not investment advice.